150198-30-4

Usage

InChI:InChI=1/C13H23NO3S2/c15-12-10(8-18)6-4-2-1-3-5-7-19-9-11(14-12)13(16)17/h10-11,18H,1-9H2,(H,14,15)(H,16,17)/t10-,11+/m1/s1

Upstream product

• 150127-06-3 (3R)-6-methylidene-5-oxo-1-thia-4-azacyclotridecane-3-carboxylic acid 
• 150127-08-5 tert-butyl methyl (7-iodoheptyl)malonate 
• 150127-07-4 tert-butyl methyl (7-bromoheptyl)malonate 
• 4549-31-9 1,7-dibromoheptane 
• 150127-15-4 methyl (3R,6S)-6-<(acetylthio)methyl>-5-oxo-1-thia-4-azacyclotridecane-3-carboxylate 
• 150198-31-5 methyl (3R,6R)-6-<(acethylthio)methyl>-5-oxo-1-thia-4-azacyclotridecane-3-carboxylate 

Relevant academic research and scientific papers

Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors

A series of 13- and 14-membered ring lactam derivatives 9a,b, 10, 11, and 12a-c was prepared from L-cysteine. Compounds 9a,b and 12a,b were tested in vitro for inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) inhibit

CERTAIN MACROCYCLIC LACTAM DERIVATIVES

The invention relates to macrocyclic lactam derivatives of formula I STR1 wherein R is hydrogen or acyl; m is an integer from 4 to 9 inclusive; n is 1 or 2; p is zero, 1 or 2; X is--CONH--or--NHCO--; Y is S, O or CH 2 ; R 1 is--COOH; or R 1 is STR2 in which R 2 is hydrogen, lower alkyl, aryl-lower alkyl, amino-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, mercapto-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, or carboxy-lower alkyl, R 3 is hydrogen or lower alkyl, and q is zero or an integer from 1 to 5 inclusive; or R 1 is STR3 in which R 4 is hydrogen, lower alkyl, lower alkoxy, hydroxy or acyloxy, and r is 1 or 2; or R 1 is STR4 in which s is 1 or 2; or R 1 is STR5 in which R 5 and R 6 independently represent hydrogen, lower alkyl, C 5-or C 6-cycloalkyl, (hydroxy-, acyloxy or lower alkoxy-) lower alkyl, carbocyclic or heterocyclic monocyclic aryl, or (hydroxy-, acyloxy-or alkoxy-) lower alkyloxy-lower alkyl; or R 5 and R 6 together with the nitrogen to which they are attached represent pyrrolidino, piperidino, morpholino, piperazino or N-alkylpiperazino; and macrocyclic sulfur and oxygen containing lactam ring isomers in which a CH 2 group of (CH 2) m in formula I is replaced by O or S, and Y represents CH 2 ; and pharmaceutically acceptable prodrug esters of any above said compound with a free carboxyl group; and pharmaceutically acceptable salts of any said compounds with a free acid or basic salt forming group; pharmaceutical compositions comprising said compounds; methods for the preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.